The global tissue engineered skin substitute market is projected to grow from USD 2.4 billion in 2024 to USD 3.5 billion by 2034, at a CAGR of 3.9%. The rising demand for advanced wound care solutions ...
Type of Acute Wound, Type of Chronic Wound, Type of AI Technology, End User and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering. The AI in wound care market is ...
Relief Therapeutics announces positive final results of RLF-TD011 trial in epidermolysis bullosa: Geneva Tuesday, November 12, 2024, 10:00 Hrs [IST] Relief Therapeutics Holding SA ...
BioStem expects to finalize definitive agreements within 60 days following customary due diligence. The transaction is subject to regulatory approvals and Board consent. BioStem and ProgenaCare will ...